4.6 Review

Current Advances in Burkholderia Vaccines Development

期刊

CELLS
卷 9, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/cells9122671

关键词

Burkholderia mallei; Burkholderia pseudomallei; Burkholderia cepacia complex; DNA vaccines; whole-cell vaccines; liver attenuated vaccines

资金

  1. Medical Research Council [CD1617-CIC04]
  2. Biotechnology and Biological Sciences Research Council [BB/T005807/1]
  3. European Union [860325]
  4. BBSRC [BB/T005807/1] Funding Source: UKRI
  5. Marie Curie Actions (MSCA) [860325] Funding Source: Marie Curie Actions (MSCA)

向作者/读者索取更多资源

The genus Burkholderia includes a wide range of Gram-negative bacterial species some of which are pathogenic to humans and other vertebrates. The most pathogenic species are Burkholderia mallei, Burkholderia pseudomallei, and the members of the Burkholderia cepacia complex (Bcc). B. mallei and B. pseudomallei, the cause of glanders and melioidosis, respectively, are considered potential bioweapons. The Bcc comprises a subset of Burkholderia species associated with respiratory infections in people with chronic granulomatous disease and cystic fibrosis. Antimicrobial treatment of Burkholderia infections is difficult due to the intrinsic multidrug antibiotic resistance of these bacteria; prophylactic vaccines provide an attractive alternative to counteract these infections. Although commercial vaccines against Burkholderia infections are still unavailable, substantial progress has been made over recent years in the development of vaccines against B. pseudomallei and B. mallei. This review critically discusses the current advances in vaccine development against B. mallei, B. pseudomallei, and the Bcc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据